Tracking Real-Life Myasthenia Gravis Symptoms in Patients on Rozanolixizumab

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study observes adults with generalized MG who are treated with Rozanolixizumab to understand how symptoms, fatigue, and daily functioning behave outside of tightly controlled trials. It uses patient-reported perspectives alongside physician assessments to capture real-world effectiveness and tolerability. Participants are adults with confirmed anti-AChR or anti-MUSK antibodies, meeting MFGA criteria, and who are suitable for ROZ treatment. Data are collected during routine visits to multiple French centers to reflect diverse clinical settings. The study does not assign treatments and aims to describe outcomes in a naturalistic context.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male or female subjects aged ≥18 years;
* Diagnosed with MG with confirmed documentation and supported by a physical exam and confirmed seropositivity for anti AChR or anti MUSK antibodies;
* Meets the clinical criteria as defined by the Myasthenia Gravis Foundation of America (MFGA) for generalized MG class IIa, IIb, IIIa, and IIIb;
* Patient suitable for ROZ treatment (IgG ≥ 5,5 g/l);
* Patient naïve for ROZ treatment, or receiving the last dose more than 3 months prior inclusion;
* MG-ADL score ≥ 3 (with ≥ 3 points of non-ocular symptoms);
* Patient must have received all mandatory vaccinations according to local regulations prior to study enrollment;
* Capable of understanding the written informed consent, and providing signed, dated, and witnessed written informed consent;
* Willing and able to comply with scheduled visits, treatment plan, study restrictions, laboratory tests, contraceptive guidelines, and other study procedures;
* Patient affiliated to a European social security system.

Exclusion Criteria:

* Any current mental condition (psychiatric disorder, senility, or dementia) that, in the opinion of the investigator, may affect study compliance or prevent understanding of the aims, investigational procedures, or possible consequences of the study; and/or patient with a Mini-mental State evaluation (MMSE) of \<25;
* History of any illness or any clinical condition that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject;
* History of ongoing malignancy (except basal cell and squamous cell carcinomas of the skin, or in situ carcinoma of the cervix uteri that have been completely excised and cured);
* Clinically significant uncontrolled active or chronic bacterial, viral, or fungal infection at inclusion;
* Patient receiving concomitant treatment with rituximab, anti-FcRn, complement inhibitors and/or PLEX;
* Patients discontinued from rituximab without respecting the administration rules of ROZ;
* Patient with end-stage diseases or with a disease that will enable him to be evaluated and/or treated;
* Patients with non-treated active infections;
* Patients with hypersensitivity to the active substance(s) or to any of the excipients, specifically: histidine, histidine hydrochloride monohydrate, proline, polysorbate 80, or water for injections.
* Subject, or close relative of the subject, is the investigator or a sub-investigator, research assistant, pharmacist, study coordinator, or other staff directly involved with the conduct of the study at that site;
* Patient protected by law, under guardianship or curator ship, or not able to participate in a clinical study according to the article L.1121-16 of the French Public Health Code

Where it's running

• CHU de NICE
  Nice, Alpes-maritimes, France Recruiting
• CHu d'Angers
  Angers, France Not yet recruiting
• Ch de Boulogne sur Mer
  Boulogne-sur-Mer, France Not yet recruiting
• Hôpital Henri Mondor
  Créteil, France Not yet recruiting
• Hôpital Raymond Pointcarré
  Garches, France Not yet recruiting
• CHU de Grenoble
  Grenoble, France Not yet recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• SHR-2173 injection added to standard care for generalized myasthenia gravis

  This Phase 2 trial tests whether SHR-2173 added to usual treatment helps adults with generalized myasthenia gravis more than a placebo add-on.

  Recruiting at 2 sites Phase 2 Guangdong Hengrui Pharmaceutical Co., Ltd · Changsha, Hunan and 1 other locations · NCT07622342

• Ravulizumab for Generalized Myasthenia Gravis in Chinese Adults

  This trial tests ravulizumab in Chinese adults with generalized myasthenia gravis to see if it helps symptoms while checking safety and how the drug behaves in the body.

  Recruiting at 8 sites Phase 3 Alexion Pharmaceuticals, Inc. · Beijing and 9 other locations · NCT07596784

• Rozanolixizumab for long-term safety and efficacy in adult ocular myasthenia gravis

  This study tests whether Rozanolixizumab is safe and helps adults with ocular myasthenia gravis over the long term.

  Recruiting at 18 sites Phase 3 UCB Pharma · Scottsdale, Arizona and 17 other locations · NCT07465289

• Rozanolixizumab for adult ocular myasthenia gravis

  This trial tests Rozanolixizumab versus placebo to see if it helps adults with ocular myasthenia gravis see improvements in eye muscles with tolerable safety.

  Recruiting at 36 sites Phase 3 UCB Pharma · Scottsdale, Arizona and 35 other locations · NCT07463521

• ADAPT Forward master protocol testing multiple regimens for generalized myasthenia gravis

  This platform tests several drug regimens, including efgartigimod IV and empasiprubart IV, in adults with generalized myasthenia gravis to find safer and more effective treatment combinations.

  Recruiting at 37 sites argenx · Carlsbad, California and 36 other locations · NCT07294170

• Adding empasiprubart to efgartigimod for AChR-antibody positive generalized myasthenia gravis

  This trial will test whether adding empasiprubart to efgartigimod infusions helps people with AChR-antibody positive generalized myasthenia gravis who have only had a partial response to efgartigimod.

  Recruiting at 33 sites Phase 2 argenx · Carlsbad, California and 32 other locations · NCT07284420

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.